You can buy or sell MCRB and other stocks, options, ETFs, and crypto commission-free!
Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. Read More It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMar 13
Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher
Seres Therapeutics, Inc. MCRB was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.11 to $6.38 in the past one-month time frame. The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has al...
Seeking AlphaMar 11
Seres teams up with AstraZeneca in cancer; shares up 17%
Thinly traded micro cap Seres Therapeutics (MCRB +17.2% ) is up on average volume in early trade on the heels of its three-year research collaboration with AstraZeneca (AZN +0.4% ) aimed at advancing the understanding of how the microbiome may boost the effectiveness of cancer immunotherapy, including potential synergy with AZN compounds.
Stock Price, News, & Analysis for Seres Therapeutics
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company is also developing SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a multi-stra...
-$0.50 per share
-$0.52 per share